Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52,942,731
-
Total 13F shares
-
51,696,984
-
Share change
-
+246,162
-
Total reported value
-
$323,689,509
-
Put/Call ratio
-
17%
-
Price per share
-
$6.26
-
Number of holders
-
104
-
Value change
-
+$3,281,155
-
Number of buys
-
58
-
Number of sells
-
53
Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q2 2023
As of 30 Jun 2023,
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) was held by
104 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,696,984 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, BlackRock Inc., JPMORGAN CHASE & CO, Boxer Capital, LLC, Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, Euclidean Capital LLC, Verition Fund Management LLC, CITADEL ADVISORS LLC, and VANGUARD GROUP INC.
This page lists
104
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.